Regarding maximum change in tumor size from baseline, a decline of over 80% was observed in 84.2% (16/19) of patients with PD-L1 CPS ≥ 10 and in 71.4% (10/14) of patients with PD-L1 CPS < 10, with no statistically significant difference (p = 0.422; Fig. 2c). Here, CD274 is linked to neoplasm.